SALT LAKE CITY, May 2, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Bank of America Merrill Lynch 2012 Health Care Conference, at 4:20 p.m. Pacific Time on Wednesday, May 16, 2012. The conference is being held at The Encore at the Wynn Hotel in Las Vegas, Nevada.
The presentation will be available to interested parties through a live webcast accessible on the investor relations section of Myriad's website at www.myriad.com.
About Myriad Genetics
Myriad Genetics, Inc. is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of nine molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a focus on improving an individual's decision making process for monitoring and treating disease. With fiscal year 2011 annual revenue of over $400 million and more than 1,000 employees, Myriad is working on strategic directives, including new product introductions, companion diagnostics, and international expansion, to take advantage of significant growth opportunities. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
CONTACT: Rebecca Chambers Director, Investor Relations and Corporate Communications (801) 584-1143 firstname.lastname@example.org
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here